References

Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought

10.1097/00129492-200501000-00016 · 2005 · External reference

Epidemiology of vestibular schwannomas–prospective 40-year data from an unselected national cohort

10.2147/clep.s218670 · 2019 · External reference

Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation

10.1136/jmg.40.11.802 · 2003 · External reference

Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane

10.1083/jcb.200503165 · 2005 · External reference

NF2 genetic alterations in sporadic vestibular schwannomas: clinical implications

10.1097/mao.0b013e318298ac79 · 2013 · External reference

Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma

10.1093/hmg/3.2.347 · 1994 · External reference

NF2-related schwannomatosis and other schwannomatosis: an updated genetic and epidemiological study

10.1136/jmg-2024-110065 · 2024 · External reference

A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas

10.3171/2015.12.jns151857 · 2016 · External reference

Recurrences and progression following microsurgery of vestibular schwannoma

10.3389/fsurg.2023.1216093 · 2023 · External reference

Wait and scan” management of patients with vestibular schwannoma and the relevance of non-contrast MRI in the follow-up

10.1016/j.joto.2017.08.002 · 2017 · External reference

EANO guideline on the diagnosis and treatment of vestibular schwannoma

10.1093/neuonc/noz153 · 2020 · External reference

Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions—A Scoping Review

10.3390/cimb48030292 · 2026 · External reference

Vestibular schwannomas

10.1056/nejmra2020394 · 2021 · External reference

The molecular biology and novel treatments of vestibular schwannomas: a review

10.3171/2011.6.jns11131 · 2011 · External reference

[Pathogenesis and molecular pathology of vestibular schwannoma]

10.1007/s00106-016-0201-3 · 2017 · External reference

Schwannomas and Their Pathogenesis

10.1111/bpa.12125 · 2014 · External reference

Histomorphological Spectrum and Diagnostic Utility of S100, SOX10, CD34, Calretinin, and Ki67 in the Evaluation of Schwannomas: A Retrospective Study of 26 Cases in a Tertiary Health Institute, Zaria-Nigeria

10.4103/jwas.jwas_177_24 · 2025 · External reference

Nerve origin of vestibular schwannoma: a prospective study

10.1017/s0022215107001028 · 2007 · External reference

The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level

10.1097/01.mao.0000180484.24242.54 · 2006 · External reference

Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas

10.3390/cancers17030393 · 2025 · External reference

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus

10.1016/j.cell.2010.01.029 · 2010 · External reference

Schwann cells in the inner ear: development, disease, and regeneration

10.3389/fncel.2025.1662274 · 2025 · External reference

The comparable tumour microenvironment in sporadic and NF2-related schwannomatosis vestibular schwannoma

10.1093/braincomms/fcad197 · 2023 · External reference

Interactions among Merlin, Arkadia, and SKOR2 mediate NF2-associated human Schwann cell proliferation

10.1186/s13287-025-04281-x · 2025 · External reference

Hearing loss and vestibular schwannoma: new insights into Schwann cells implication

10.1038/s41419-023-06141-z · 2023 · External reference

Immune profiling of human vestibular schwannoma secretions identifies TNF-α and TWEAK as cytokines with synergistic potential to impair hearing

10.1186/s12974-025-03364-z · 2025 · External reference

Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth

10.1016/j.molonc.2015.03.009 · 2015 · External reference

Extracellular vesicles derived from human vestibular schwannomas associated with poor hearing damage cochlear cells

2016 · External reference

SMARCB1-related schwannomatosis and other SMARCB1-associated phenotypes: clinical spectrum and molecular pathogenesis

10.1007/s10689-025-00486-4 · 2025 · External reference

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

10.3390/ijms22115850 · 2021 · External reference

Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1

10.1002/lary.20834 · 2010 · External reference

The VEGF/VEGF-R Axis in Sporadic Vestibular Schwannomas Correlates with Irradiation and Disease Recurrence

10.1159/000346238 · 2013 · External reference

Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue

10.3892/mmr.2015.3415 · 2015 · External reference

Potential molecular biomarkers of vestibular schwannoma growth: progress and prospects

2021 · External reference

Single-cell sequencing reveals the cell map and transcriptional network of sporadic vestibular schwannoma

10.3389/fnmol.2022.984529 · 2022 · External reference

Immunohistochemical Profiles of Matrix Metalloproteinases and Vascular Endothelial Growth Factor Overexpression in the Antoni B Area of Vestibular Schwannomas

10.1016/j.wneu.2020.07.208 · 2020 · External reference

Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells

10.4161/15384047.2014.972765 · 2015 · External reference

Matrix metalloproteinase 9: An emerging biomarker for classification of adherent vestibular schwannoma

2024 · External reference

Cystic vestibular schwannomas: a possible role of matrix metalloproteinase–2 in cyst development and unfavorable surgical outcome

10.3171/jns.2007.106.5.866 · 2007 · External reference

Identifying Tumor Microenvironment Biomarkers in Adherent and Cystic Vestibular Schwannomas

10.1097/mao.0000000000004073 · 2024 · External reference

Gene expression profiles between cystic and solid vestibular schwannoma indicate susceptible molecules and pathways in the cystic formation of vestibular schwannoma

10.1007/s10142-019-00672-5 · 2019 · External reference

Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas

10.1007/s00428-012-1236-9 · 2012 · External reference

MMP-14 (MT1-MMP) Is a Biomarker of Surgical Outcome and a Potential Mediator of Hearing Loss in Patients With Vestibular Schwannomas

10.3389/fncel.2020.00191 · 2020 · External reference

Potential target within the tumor microenvironment - MT1-MMP

2025 · External reference

Tumor Microenvironment in Sporadic Vestibular Schwannoma: A Systematic, Narrative Review

10.3390/ijms24076522 · 2023 · External reference

Tumor Biology and Microenvironment of Vestibular Schwannoma-Relation to Tumor Growth and Hearing Loss

10.3390/biomedicines11010032 · 2022 · External reference

The inflammatory microenvironment in vestibular schwannoma

2020 · External reference

Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma

10.1093/neuonc/noy177 · 2019 · External reference

Analysis of tumor microenvironment composition in vestibular schwannomas: insights into NF2-associated and sporadic variations and their clinical correlations

2024 · External reference

Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas

10.1097/mao.0b013e31827c9fbf · 2013 · External reference

Exploring the Role of Inflammatory Genes and Immune Infiltration in Vestibular Schwannomas Pathogenesis

10.2147/jir.s476745 · 2024 · External reference

Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the Tübingen Schwannoma Cohort

10.3390/cancers13030466 · 2021 · External reference

Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing

10.1177/2473974x211059111 · 2021 · External reference

The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study

10.3171/2020.3.jns193230 · 2021 · External reference

Immunophenotype of Vestibular Schwannomas

2020 · External reference

Inhibition of NF-kappaB activation by merlin

10.1016/s0006-291x(02)02077-6 · 2002 · External reference

The anti-tumor effect of aspirin: What we know and what we expect

10.1016/j.biopha.2017.08.085 · 2017 · External reference

Cyclooxygenase-2 supports tumor proliferation in vestibular schwannomas

10.1227/neu.0b013e318208f5c7 · 2011 · External reference

Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology

10.1186/s13046-022-02473-4 · 2022 · External reference

Alternatively activated macrophages are associated with faster growth rate in vestibular schwannoma

10.1093/braincomms/fcae400 · 2024 · External reference

Single-Cell RNA-Seq Reveals Heterogeneity of Cell Communications between Schwann Cells and Fibroblasts within Vestibular Schwannoma Microenvironment

10.1016/j.ajpath.2022.06.006 · 2022 · External reference

Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state

10.1038/s41467-023-42762-w · 2024 · External reference

Cancer-Associated Fibroblast Subtypes Reveal Distinct Gene Signatures in the Tumor Immune Microenvironment of Vestibular Schwannoma

10.3390/cells13191669 · 2024 · External reference

Integrating single-cell and spatial transcriptomics reveals the cellular heterogeneity of vestibular schwannoma

10.1038/s41698-025-01028-y · 2025 · External reference

Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment

10.1007/s11060-022-04221-2 · 2023 · External reference

Spatial mapping of immune cell environments in NF2-related schwannomatosis vestibular schwannoma

10.1038/s41467-025-57586-z · 2025 · External reference

Quantitative Assessment of Collagen Architecture to Determine Role of Tumor Stroma During Vestibular Schwannoma Progression

10.1002/ohn.1018 · 2025 · External reference

Immune Profiling of Secreted Factors from Human Vestibular Schwannoma Cells and Tumor-associated Macrophages

2024 · External reference

Efficacy and safety of bevacizumab for vestibular schwannomas in neurofibromatosis type-2: a systematic review and meta-analysis

10.1007/s00405-026-10174-3 · 2026 · External reference

Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2

10.1097/mao.0000000000001781 · 2018 · External reference

Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma

10.1093/neuonc/noad066 · 2023 · External reference

Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab

10.1007/s11060-025-05100-2 · 2025 · External reference

VEGFR-3 signaling in macrophages: friend or foe in disease?

2024 · External reference

Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model

10.1007/s11060-026-05574-8 · 2026 · External reference

Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models

10.1073/pnas.1719966115 · 2018 · External reference

Targeting HGF/c-MET signaling to regulate the tumor microenvironment: Implications for counteracting tumor immune evasion

10.1186/s12964-025-02033-1 · 2025 · External reference

Aspirin does not prevent growth of vestibular schwannomas: A case-control study

10.1002/lary.27114 · 2018 · External reference

Vestibular Schwannoma Growth With Aspirin and Other Nonsteroidal Anti-inflammatory Drugs

10.1097/mao.0000000000001506 · 2017 · External reference

Impact of Aspirin and Other NSAID Use on Volumetric and Linear Growth in Vestibular Schwannoma

10.1177/0194599819827812 · 2019 · External reference

Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double-Blind, Placebo-Controlled Study Proposal

2025 · External reference

Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas

2025 · External reference

Antiangiogenic agents for nonmalignant brain tumors

10.1055/s-0033-1338262 · 2013 · External reference

Potential role of imatinib mesylate (Gleevec, STI-571) in the treatment of vestibular schwannoma

10.1097/mao.0b013e3182009665 · 2011 · External reference

Investigation of the in vitro therapeutic efficacy of nilotinib in immortalized human NF2-null vestibular schwannoma cells

10.1371/journal.pone.0039412 · 2012 · External reference

Updates on Tumor Biology in Vestibular Schwannoma

10.1016/j.otc.2023.02.004 · 2023 · External reference

NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss

10.1016/j.heares.2019.07.007 · 2019 · External reference

Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma

10.1038/s41598-018-23609-7 · 2018 · External reference

The ErbB/HER family of protein-tyrosine kinases and cancer

10.1016/j.phrs.2013.11.002 · 2014 · External reference

Treatment of vestibular schwannoma cells with ErbB inhibitors

10.1097/mao.0b013e31823e287f · 2012 · External reference

10.1172/jci130787

10.1172/jci130787 · External reference

ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma

10.1093/neuonc/noq012 · 2010 · External reference

Nrg1/ErbB signaling networks in Schwann cell development and myelination

10.1016/j.semcdb.2010.08.008 · 2010 · External reference

Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation

10.1002/glia.20316 · 2006 · External reference

The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study

10.1097/mao.0b013e31817f7398 · 2008 · External reference

Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3

10.1002/j.1460-2075.1995.tb00101.x · 1995 · External reference

ErbB expression, activation, and inhibition with lapatinib and tyrphostin (AG825) in human vestibular schwannomas

10.1097/mao.0b013e31821f7d88 · 2011 · External reference

Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma

10.3171/2022.9.jns22699 · 2023 · External reference

Circ_0001665 Contributes to the Occurrence of Vestibular Schwannoma via Targeting miR-302a-3p/Adam9/EGFR Signaling Pathway

10.1016/j.neuroscience.2021.12.035 · 2022 · External reference

ERBB3 targeting: A promising approach to overcoming cancer therapeutic resistance

10.1016/j.canlet.2024.217146 · 2024 · External reference

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

10.1073/pnas.1016140108 · 2011 · External reference

The mTOR pathway in Gliomas: From molecular insights to targeted therapies

10.1016/j.biopha.2025.118237 · 2025 · External reference

The mTOR Pathway in Hearing Disorders: Mechanistic Links to Aging, Regeneration, and Neurodegeneration

10.1007/s12035-025-05653-3 · 2026 · External reference

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth

10.1128/mcb.01581-08 · 2009 · External reference

Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types

10.1158/1541-7786.mcr-11-0425-t · 2012 · External reference

Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L

10.1073/pnas.0405971102 · 2004 · External reference

Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas

10.1002/lary.22392 · 2012 · External reference

Merlin tumor suppressor function is regulated by PIP2-mediated dimerization

10.1371/journal.pone.0281876 · 2023 · External reference

Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis

10.3390/cancers12010177 · 2020 · External reference

A chemical biology approach identified PI3K as a potential therapeutic target for neurofibromatosis type 2

2014 · External reference

Cotargeting Phosphoinositide 3-Kinase and Focal Adhesion Kinase Pathways Inhibits Proliferation of NF2 Schwannoma Cells

10.1158/1535-7163.mct-23-0135 · 2023 · External reference

Simultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis

10.1038/s41388-024-02958-w · 2024 · External reference

Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells

10.1016/j.ejca.2009.03.013 · 2009 · External reference

Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas

10.1093/neuonc/not150 · 2014 · External reference

Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas

10.1007/s11060-014-1710-0 · 2015 · External reference

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells

10.18632/oncotarget.28254 · 2022 · External reference

Fimepinostat Promotes Apoptosis and Decreases Cytokine Secretion in NF2-Related Human Schwannoma Cells

10.3390/ijms27062636 · 2026 · External reference

Effect of AR42 in Primary Vestibular Schwannoma Cells and a Xenograft Model of Vestibular Schwannoma

10.1097/mao.0000000000003556 · 2022 · External reference

Merlin, a multi-suppressor from cell membrane to the nucleus

10.1016/j.febslet.2012.03.016 · 2012 · External reference

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

10.1016/j.bbamcr.2006.10.001 · 2007 · External reference

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac

10.1158/0008-5472.can-06-1608 · 2007 · External reference

RAS proteins and their regulators in human disease

10.1016/j.cell.2017.06.009 · 2017 · External reference

Inhibition of MEK pathway in vestibular schwannoma cell culture

10.1002/lary.23472 · 2012 · External reference

The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling

10.1038/s41388-019-0883-6 · 2019 · External reference

PAK kinase regulates Rac GTPase and is a potential target in human schwannomas

10.1016/j.expneurol.2009.04.019 · 2009 · External reference

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac

10.1158/0008-5472.can-06-1608 · 2007 · External reference

Merlin inhibits growth hormone-regulated Raf–ERKs pathways by binding to Grb2 protein

10.1016/j.bbrc.2005.12.122 · 2006 · External reference

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

10.18632/oncotarget.659 · 2012 · External reference

Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling

10.1172/jci.insight.141514 · 2020 · External reference

Merlin–YAP signaling: emerging mechanisms, functions, and therapeutic approaches

2025 · External reference

Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma

10.1016/j.wneu.2018.06.010 · 2018 · External reference

Unresolved reference

External reference

YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2-EGFR Signaling Axis

10.1158/0008-5472.can-15-1144 · 2016 · External reference

The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer

10.1038/s12276-025-01551-9 · 2025 · External reference

Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein

10.1101/gad.2000111 · 2011 · External reference

Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression

2011 · External reference

10.1126/science.adf4478

10.1126/science.adf4478 · External reference

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

10.1038/s43018-023-00577-0 · 2023 · External reference

Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances

10.1038/s41392-025-02142-w · 2025 · External reference

Merlin-Deficient Human Tumors Show Loss of Contact Inhibition and Activation of Wnt/β-Catenin Signaling Linked to the PDGFR/Src and Rac/PAK Pathways

10.1593/neo.111060 · 2011 · External reference

Wnt/β-catenin signaling: components, mechanisms, and diseases

10.1016/j.devcel.2009.06.016 · 2009 · External reference

Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation

10.1038/cdd.2016.54 · 2016 · External reference

NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation

10.1038/onc.2010.20 · 2010 · External reference

Celastrol suppresses the growth of vestibular schwannoma in mice by promoting the degradation of β-catenin

10.1038/s41401-022-00908-4 · 2022 · External reference

MicroRNA-200a suppresses the Wnt/β-catenin signaling pathway by interacting with β-catenin

2011 · External reference

Molecular biology and disease models of vestibular schwannomas: state of the art

2025 · External reference

Advancements in preclinical models for NF2-related schwannomatosis research

10.3390/cancers18020224 · 2026 · External reference